

Anti-TFPI Antibody (Concizumab)

Introduction

Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 domain of TFPI, thereby blocking the interaction of this domain with the FXa active site. Concizumab can be used in the study of hemophilia.

Product parameters

Alternative Names	NNC-0172-0000-2021, NN-7415
Target Accession	P10646
Target	TFPI
CAS number	1312299-39-0
Molecular Weight	145 kDa
Host	CHO
Reactivity	Human, Cynomolgus, Rhesus, Rabbit
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG4SP
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human TFPI, Fc Tag at 2 ug/mL can bind Anti-TFPI Antibody (Concizumab), EC50=0.01401 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

